Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/12/2024 | $375.00 → $430.00 | Mkt Outperform | JMP Securities |
| 7/17/2024 | $380.00 | Buy | BofA Securities |
| 7/17/2024 | $385.00 | Buy | Jefferies |
| 4/10/2024 | $315.00 → $400.00 | Buy | Needham |
| 3/13/2024 | $380.00 | Buy | Argus |
| 8/22/2023 | $230.00 | Equal-Weight | Morgan Stanley |
| 7/5/2023 | $236.00 | Overweight | JP Morgan |
| 5/11/2023 | $236.00 | Neutral → Overweight | JP Morgan |
Axon Enterprise (NASDAQ:AXON) has outperformed the market over the past 5 years by 23.15% on an annualized basis producing an average annual return of 36.08%. Currently, Axon Enterprise has a market capitalization of $24.12 billion. Buying $1000 In AXON: If an investor had bought $1000 of AXON stock 5 years ago, it would be worth $4,597.84 today based on a price of $319.55 for AXON at the time of writing. Axon Enterprise's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated
Investors with a lot of money to spend have taken a bearish stance on Axon Enterprise (NASDAQ:AXON). And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AXON, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga's options scanner spotted 11 uncommon options trades for Axon Enterprise. This isn't normal. The overall sentiment of these big-money traders is split between 36% bullish and 54%, bearish. Out of all o
Jefferies analyst Michael Yee initiates coverage on Axon Enterprise (NASDAQ:AXON) with a Buy rating and announces Price Target of $385.
JMP Securities reiterated coverage of Axon with a rating of Mkt Outperform and set a new price target of $430.00 from $375.00 previously
BofA Securities initiated coverage of Axon with a rating of Buy and set a new price target of $380.00
Jefferies initiated coverage of Axon with a rating of Buy and set a new price target of $385.00
SC 13G/A - AXON ENTERPRISE, INC. (0001069183) (Subject)
SC 13G/A - AXON ENTERPRISE, INC. (0001069183) (Subject)
SC 13G/A - AXON ENTERPRISE, INC. (0001069183) (Subject)
4 - AXON ENTERPRISE, INC. (0001069183) (Issuer)
4 - AXON ENTERPRISE, INC. (0001069183) (Issuer)
4 - AXON ENTERPRISE, INC. (0001069183) (Issuer)
10-Q - AXON ENTERPRISE, INC. (0001069183) (Filer)
8-K - AXON ENTERPRISE, INC. (0001069183) (Filer)
8-K - AXON ENTERPRISE, INC. (0001069183) (Filer)
Axon Body 4 body-worn cameras will be deployed to more than 10,000 RCMP officers across Canada, along with digital evidence management system Axon Evidence SCOTTSDALE, Ariz., Nov. 14, 2024 /PRNewswire/ -- Axon (NASDAQ:AXON), the global public safety technology leader, today announced that, following a competitive procurement process, it has been awarded a Public Services and Procurement Canada-led contract to supply the Royal Canadian Mounted Police (RCMP) with Axon Body 4 body-worn cameras and digital evidence management system Axon Evidence. Axon President Josh Isner said: "
SCOTTSDALE, Ariz., Nov. 7, 2024 /PRNewswire/ -- Axon Cloud & Services revenue grows 36% to $203 millionAnnual recurring revenue grows 36% to $885 millionNet income of $67 million supports non-GAAP net income of $113 million and Adjusted EBITDA of $145 millionRaises full year revenue outlook to approximately $2.07 billion, over 32% annual growth; expects full year Adjusted EBITDA margin of approximately 24.6%Fellow shareholders, Axon is proud to report strong third quarter results and raise our outlook for the remainder of the year once again. Robust demand for our products and
SCOTTSDALE, Ariz., Oct. 24, 2024 /PRNewswire/ -- Axon (NASDAQ:AXON), the global public safety technology leader, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. Axon will host a live Zoom video webinar to discuss the company's financial results at 5 p.m. ET that same day. The live webinar to discuss financial results, followed by Q&A, will be linked from Axon's investor relations website at https://investor.axon.com. An archived replay will be available after the call ends. Upcoming Conference Par
IRVINE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer. "We are thrilled to welcome Andrea as we approach the inflection point of commercial launch," Oncocyte CEO Josh Riggs said. "She has a proven track record of guiding financial strategy through multiple phases of growth, raising and stewarding capital, and building relationships with high quality institutional investors. Andrea is therefore an ideal CFO business partner to myself, the Board of Directors and the Oncocyte team. "We expect 2024 and 2025 t
Premier tech-enabled real estate property services platform adds veteran finance executive to help spearhead next phase of growth Lessen, the premier tech-enabled, end-to-end solution for outsourced real estate property services, announced today the appointment of Arvind Bobra as chief financial officer. Bobra brings an established strategic leadership track record, strengthening Lessen for its next stage of growth. "We're thrilled to welcome Arvind Bobra to the team," said Jay McKee, CEO of Lessen. "He brings a level of expertise that will propel Lessen to the next level and we're excited for the next step of our company's evolution." Bobra is a veteran public company finance executi
SCOTTSDALE, Ariz., March 15, 2023 /PRNewswire/ -- Axon (Nasdaq: AXON), the global public safety technology leader, is pleased to announce the appointment of three additional members to its board of directors, Erika Ayers, CEO of Barstool Sports, Graham Smith, former Salesforce executive and Jeri Williams, former Phoenix Police Department Chief of Police. "It's an honor to welcome Ms. Ayers, Mr. Smith and Chief Williams to Axon's board and we look forward to their contributions as we continue to innovate through technology and create solutions for safety that can help protect life," said Axon CEO and founder Rick Smith. "They each bring a diverse set of skills and expertise and can provide me
SCOTTSDALE, Ariz., Nov. 7, 2024 /PRNewswire/ -- Axon Cloud & Services revenue grows 36% to $203 millionAnnual recurring revenue grows 36% to $885 millionNet income of $67 million supports non-GAAP net income of $113 million and Adjusted EBITDA of $145 millionRaises full year revenue outlook to approximately $2.07 billion, over 32% annual growth; expects full year Adjusted EBITDA margin of approximately 24.6%Fellow shareholders, Axon is proud to report strong third quarter results and raise our outlook for the remainder of the year once again. Robust demand for our products and
SCOTTSDALE, Ariz., Oct. 24, 2024 /PRNewswire/ -- Axon (NASDAQ:AXON), the global public safety technology leader, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. Axon will host a live Zoom video webinar to discuss the company's financial results at 5 p.m. ET that same day. The live webinar to discuss financial results, followed by Q&A, will be linked from Axon's investor relations website at https://investor.axon.com. An archived replay will be available after the call ends. Upcoming Conference Par
Interest in kidney transplant assay represents approximately 25% of US transplant volumeCompany lays out land and expand strategy in transplant IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders. Dear shareholders,We are thrilled to report that we have successfully launched GraftAssure™, which is our research-use-only assay that can detect early evidence of graft organ damage in a patient's blood. On July 11, 2024, our GraftAssure assay was run at a major metropolitan transplant center and research university in the northeast United State